July 28, 2026 Ultragenyx Pharmaceutical Inc. Prepares for Second Quarter 2026 Financial Results Ultragenyx Pharmaceutical Inc. will host a conference call on August 4, 2026, to discuss its Q2 financial results and strategic initiatives. This event is pivotal for stakeholders seeking insights into the company's performance and advancements in rare disease treatments.
July 24, 2026 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Ultragenyx Pharmaceutical has announced an inducement grant to attract new talent, aligning with Nasdaq's regulations. This strategic move is vital for the company's growth in the competitive biopharmaceutical sector focused on rare diseases.
July 08, 2026 Ultragenyx Pharmaceutical Inc. Releases 2025 Impact Report: Commitment to Rare Disease Innovation Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report, showcasing advancements in rare disease therapies and patient support initiatives. The company emphasizes R&D investment, community engagement, and sustainability efforts to improve lives affected by rare diseases.
June 19, 2026 Ultragenyx Pharmaceutical Inc. Grants Inducement Awards to New Executives Ultragenyx Pharmaceutical Inc. has granted 44,409 restricted stock units to 15 new executives as part of its employment inducement strategy. This move highlights the company's dedication to growth and innovation in addressing rare diseases. The RSUs will vest over four years, aligning the new hires' interests with the company's long-term success.
June 03, 2026 Ultragenyx Pharmaceutical Inc. to Spotlight Innovations at Goldman Sachs Healthcare Conference Ultragenyx Pharmaceutical Inc. will showcase its innovations at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. CEO Emil Kakkis will discuss the company's efforts in rare disease therapies, providing insights into their pipeline and strategic initiatives. The event will be accessible via a live webcast for wider engagement.
May 22, 2026 Ultragenyx Pharmaceutical Inc. Grants Inducement Awards to New Executives Ultragenyx Pharmaceutical Inc. has issued 17,567 restricted stock units to 11 new executives as part of a strategic initiative to strengthen its leadership. This move aims to attract top talent and underscores the company's commitment to developing therapies for rare and ultra-rare diseases.
May 06, 2026 Ultragenyx Pharmaceutical Inc. Set to Engage at Bank of America’s 2026 Healthcare Conference Ultragenyx Pharmaceutical Inc. will participate in the Bank of America’s 2026 Healthcare Conference, featuring key executives discussing the company's strategic advancements. A live webcast of the event will be available for interested stakeholders.
May 06, 2026 Ultragenyx Pharmaceutical Inc. Reports Mixed Results for Q1 2026 Ultragenyx Pharmaceutical Inc. reports a net loss of $185 million for Q1 2026, reflecting ongoing financial struggles despite advancements in its clinical pipeline. The company is implementing a strategic restructuring to reduce expenses while continuing to develop therapies for rare diseases. Future growth depends on effective funding and operational adjustments.
May 05, 2026 Ultragenyx Pharmaceutical Inc. Reports First Quarter 2026 Results Ultragenyx Pharmaceutical Inc. reported Q1 2026 revenues of $136 million, with significant clinical advancements including promising data for GTX-102. The company maintains its full-year revenue guidance and emphasizes the importance of upcoming product launches and research developments.
April 29, 2026 Ultragenyx Pharmaceutical Inc. Announces Conference Call for Q1 2026 Financial Results Ultragenyx Pharmaceutical Inc. announces a conference call on May 5, 2026, to discuss its Q1 financial results. The call highlights the company's commitment to developing therapies for rare diseases and its strategic goals for efficient drug development.
April 24, 2026 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant for New Officers Ultragenyx Pharmaceutical Inc. has granted 36,447 RSUs to 12 new non-executive officers to strengthen its leadership team. This strategic move is part of the company's commitment to developing therapies for rare diseases and aims to align the interests of new officers with Ultragenyx’s long-term goals.
April 06, 2026 Ultragenyx Pharmaceutical Faces Legal Scrutiny Amidst Phase III Study Failures Ultragenyx Pharmaceutical is under legal scrutiny following allegations of misleading investors about the efficacy of its treatment setrusumab. The company's stock plummeted after disappointing Phase III study results, prompting a class action lawsuit. Investors are urged to consider their options as the deadline for participation approaches.
April 03, 2026 Ultragenyx Faces Class Action Lawsuit Deadline Amidst Stock Turmoil Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to undisclosed information regarding failed clinical trials. Investors who suffered losses between August 2023 and December 2025 must file claims by April 6, 2026, to recover their losses. The lawsuit's outcome could significantly impact the company and its shareholders.
April 03, 2026 Ultragenyx Pharmaceutical Faces Class Action Lawsuit Amid Allegations of Misleading Investors Ultragenyx Pharmaceutical is facing a class action lawsuit for allegedly misleading investors about the efficacy of setrusumab. The lawsuit could impact investors who suffered losses between August 2023 and December 2025. Shareholders are encouraged to join the class action before the April 6, 2026, deadline.
April 02, 2026 Ultragenyx Announces FDA Acceptance of BLA Resubmission for UX111 Gene Therapy Ultragenyx Pharmaceutical has announced the FDA's acceptance of its BLA resubmission for UX111, a gene therapy for Sanfilippo syndrome Type A. With promising clinical data, the therapy could provide a much-needed treatment option for this rare disorder by September 2026. CEO Dr. Emil D. Kakkis emphasizes the urgency for families needing effective solutions.
March 30, 2026 Ultragenyx Secures FDA Clearance for UX016: A Potential Breakthrough in GNE Myopathy Treatment Ultragenyx Pharmaceutical has received FDA clearance for its investigational drug UX016, targeting GNE myopathy, a rare neuromuscular disorder. This novel therapy aims to enhance sialic acid delivery to muscle tissues, with clinical trials set to begin soon, representing a significant advancement for affected patients.
March 25, 2026 Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Over Alleged Misleading Statements Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for allegedly misleading investors regarding the efficacy of its treatment, setrusumab, for Osteogenesis Imperfecta. Following disappointing trial results, the company's stock plummeted, prompting Robbins LLP to encourage affected shareholders to consider joining the lawsuit.
March 20, 2026 Ultragenyx Pharmaceutical Inc. Announces Inducement Grants for New Executives Ultragenyx Pharmaceutical has granted 10,839 RSUs to two new non-executive officers as part of its Employment Inducement Plan. This initiative reflects the company's strategic focus on hiring top talent to enhance its leadership team and commitment to developing therapies for rare diseases.
March 12, 2026 Ultragenyx Reports Promising Phase 3 Data for DTX301 Gene Therapy in OTC Deficiency Ultragenyx Pharmaceutical's Phase 3 *Enh3ance* study of DTX301 shows an 18% reduction in plasma ammonia levels among treated patients. Improvements in quality of life and a favorable safety profile highlight the therapy's potential in managing OTC deficiency, with further results expected in 2027.
February 23, 2026 Ultragenyx Pharmaceutical Inc. Gears Up for Investor Engagement in March 2026 Ultragenyx Pharmaceutical Inc. is set to participate in key investor conferences in March 2026, showcasing its advancements in therapies for rare genetic diseases. Dr. Eric Crombez will lead discussions at these events, highlighting the company's innovative pipeline and commitment to addressing unmet medical needs.
February 23, 2026 Ultragenyx Pharmaceutical Inc. Receives FDA Acceptance for DTX401 Gene Therapy Ultragenyx Pharmaceutical's DTX401 gene therapy for Glycogen Storage Disease Type Ia has received FDA BLA acceptance with a Priority Review designation. The therapy aims to address unmet medical needs and improve patient quality of life, pending approval by August 2026.
February 20, 2026 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant for New Executives Ultragenyx Pharmaceutical Inc. has issued 22,917 RSUs to six new non-executive officers as part of its strategy to attract and retain top talent. This initiative supports the company's commitment to developing innovative therapies for rare diseases while ensuring a stable workforce for future growth.
February 18, 2026 Ultragenyx Pharmaceutical Inc. 2025 Annual Report: A Year of Growth and Challenges Ultragenyx Pharmaceutical Inc. reported a revenue increase to $673 million in its 2025 annual report, driven by demand for its therapies. Despite this growth, the company faced net losses and high operating costs, while advancing its clinical pipeline and expanding market presence.
February 14, 2026 Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Amidst Investor Concerns Ultragenyx Pharmaceutical Inc. is embroiled in a class action lawsuit following significant stock losses due to alleged misleading statements about its drug setrusumab. Investors who purchased shares between August 2023 and December 2025 may join the lawsuit to seek compensation for their financial losses.
February 12, 2026 Ultragenyx Pharmaceutical Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Ultragenyx Pharmaceutical Inc. reported strong financial results for Q4 and the full year 2025, showcasing a 25% revenue increase. The company is implementing a strategic restructuring plan and aims for profitability by 2027, with multiple promising therapies in its pipeline.
February 10, 2026 Ultragenyx Pharmaceutical Inc. Faces Securities Fraud Class Action Lawsuit Ultragenyx Pharmaceutical Inc. is facing a securities fraud class action lawsuit over misleading information about its drug setrusumab. Investors who purchased stock between August 2023 and December 2025 may file claims until April 6, 2026. The lawsuit highlights concerns about the efficacy and safety claims made by the company regarding its drug trials.
February 06, 2026 Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Amidst Significant Shareholder Losses Ultragenyx Pharmaceutical Inc. is embroiled in a class action lawsuit due to alleged securities fraud that caused a 42% drop in stock price after disappointing clinical trial results. Investors affected between August 2023 and December 2025 have until April 6, 2026, to join the lawsuit and seek recovery.
February 06, 2026 Investors Alert: Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for alleged securities fraud related to misleading statements about its drug candidate for Osteogenesis Imperfecta. Investors who purchased shares between August 3, 2023, and December 26, 2025, are encouraged to join the lawsuit by April 6, 2026, to recover potential losses.
February 06, 2026 Ultragenyx Pharmaceutical Faces Class Action Lawsuit: Investors Urged to Act Ultragenyx Pharmaceutical Inc. is embroiled in a class action lawsuit for alleged securities violations, which have impacted its stock significantly. Investors are urged to consider joining the lawsuit if they purchased shares between August 2023 and December 2025.
February 06, 2026 Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Over Securities Law Violations Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit alleging violations of securities laws due to misleading statements about its clinical trial results. The lawsuit, representing investors from August 2023 to December 2025, raises serious concerns about the company's transparency and communication with shareholders.
February 05, 2026 Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Over Allegations of Misleading Investors Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit for allegedly misleading investors about the efficacy of its drug setrusumab. The lawsuit arose after the company’s Phase III studies failed to show significant results, causing a sharp decline in stock price. Affected shareholders may join the suit to seek recovery.
February 05, 2026 Ultragenyx Pharmaceutical Inc. Announces Upcoming Conference Call for Q4 and Full-Year 2025 Results Ultragenyx Pharmaceutical Inc. will host a conference call on February 12, 2026, to discuss its Q4 and full-year 2025 results. Stakeholders can expect insights on financial performance and strategic updates. The event will be accessible via webcast, with a replay available for three months.
February 05, 2026 Ultragenyx Pharmaceutical Inc. Faces Class Action Lawsuit Amid Controversy Over Setrusumab Ultragenyx Pharmaceutical Inc. is embroiled in a class action lawsuit initiated by Rosen Law Firm, alleging misleading statements about its drug setrusumab. The lawsuit claims that the company concealed critical data about the drug's efficacy, leading to financial losses for investors. Shareholders are encouraged to participate in the litigation process.
February 03, 2026 Ultragenyx Announces Promising Long-Term Data for UX111 Gene Therapy in Sanfilippo Syndrome Ultragenyx Pharmaceutical announced promising long-term data for UX111, an investigational gene therapy for Sanfilippo syndrome Type A, showing substantial cognitive and functional improvements in children. The therapy also demonstrated a favorable safety profile and is under review for accelerated FDA approval.
January 30, 2026 Ultragenyx Resubmits BLA for Innovative Gene Therapy Targeting Sanfilippo Syndrome Type A Ultragenyx has resubmitted its Biologics License Application for UX111, an innovative gene therapy for Sanfilippo Syndrome Type A, to the FDA. This resubmission follows extensive data addressing past concerns and highlights the urgent need for treatment for affected children. Approval could offer hope to thousands as the first-ever therapy for this devastating condition.
January 23, 2026 Ultragenyx Pharmaceutical Inc. Induces New Talent with Restricted Stock Units Ultragenyx Pharmaceutical Inc. announced the grant of 16,355 restricted stock units to nine new non-executive officers as part of its strategy to attract top talent. This move reflects the company's commitment to innovation in the rare disease sector and strengthens its leadership team to enhance drug development efforts.
January 12, 2026 Ultragenyx Pharmaceutical Inc. Reports Significant Growth and Future Catalysts at J.P. Morgan Annual Healthcare Conference Ultragenyx Pharmaceutical Inc. showcased impressive financial results for 2025, with a revenue growth of 20%. The company outlined critical clinical milestones for 2026, including gene therapy approvals and pivotal study data, positioning itself as a leader in rare disease therapies.
January 07, 2026 Ultragenyx Pharmaceutical Set to Present at J.P. Morgan Healthcare Conference Ultragenyx Pharmaceutical will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Emil D. Kakkis will discuss the company’s vision and drug developments targeting rare diseases, with a live webcast available for stakeholders.
December 30, 2025 Ultragenyx Advances Gene Therapy for Rare Disease with FDA Submission Ultragenyx has submitted a Biologics License Application for DTX401, a gene therapy targeting Glycogen Storage Disease Type Ia. This therapy aims to alleviate the burdens of current management strategies, offering hope for improved quality of life for patients. The submission is backed by extensive clinical data and FDA designations highlighting its significance.
December 29, 2025 Ultragenyx Pharmaceuticals Announces Phase 3 Study Results for Setrusumab in Osteogenesis Imperfecta Ultragenyx Pharmaceuticals revealed disappointing Phase 3 study results for Setrusumab aimed at Osteogenesis Imperfecta, failing to reduce fracture rates. However, improvements in bone mineral density were observed, prompting further data analysis and strategic adjustments for the company.
December 19, 2025 Ultragenyx Pharmaceutical Inc. Grants Restricted Stock Units to New Executives Ultragenyx Pharmaceutical has granted 13,144 restricted stock units to nine new executives as part of its strategy to attract top talent. This move aligns with the company's commitment to developing innovative therapies for rare diseases and strengthens its position in the biopharmaceutical industry.
November 24, 2025 Ultragenyx Pharmaceutical Inc. Set to Showcase Innovations at December Investor Conferences Ultragenyx Pharmaceutical Inc. is set to showcase its advancements in rare disease therapies at two major investor conferences in December 2025. Dr. Eric Crombez will discuss the company's innovative strategies and ongoing projects, emphasizing their commitment to addressing unmet medical needs in rare genetic conditions. Webcasts will be available for those unable to attend.
November 21, 2025 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant for New Executives Ultragenyx Pharmaceutical Inc. has announced an inducement grant of 18,180 RSUs to 12 new non-executive officers, aiming to enhance its leadership team. This strategic move is part of the company's commitment to developing innovative therapies for rare diseases and aligns with Nasdaq regulations.
November 05, 2025 Ultragenyx Pharmaceutical Inc. Reports Q3 2025 Financials: Growth Amid Challenges Ultragenyx Pharmaceutical Inc. reported a revenue increase to $159.9 million in Q3 2025, led by strong sales of Crysvita and Evkeeza. Despite this growth, the company faced a net loss of $180.4 million due to high R&D investments. The promising pipeline of therapies offers hope for future success.
November 04, 2025 Ultragenyx Pharmaceutical Inc. Reports Strong Third Quarter 2025 Financial Results and Corporate Developments Ultragenyx Pharmaceutical Inc. reported a 15% revenue increase in Q3 2025, driven by strong sales of Crysvita. Despite a net loss of $180 million, the company secured $400 million through a royalty financing deal, reaffirming its revenue guidance and outlining key clinical milestones ahead.
November 04, 2025 Ultragenyx Pharmaceutical Inc. Sells Additional Royalties on Crysvita® for $400 Million Ultragenyx Pharmaceutical Inc. has sold an additional 25% royalty interest in Crysvita® to OMERS Life Sciences for $400 million. This strategic move aims to bolster Ultragenyx's balance sheet while supporting future growth and continued innovation in rare disease treatments.
October 30, 2025 Ultragenyx Pharmaceutical Inc. Doses First Patient in Groundbreaking Aurora Study for Angelman Syndrome Ultragenyx Pharmaceutical has initiated the Aurora study, dosing its first patient with GTX-102 for Angelman syndrome. This study broadens treatment eligibility, targeting patients aged 1 to 65 with various genotypes. The community is optimistic about the potential impact of this innovative therapy.
October 28, 2025 Ultragenyx Pharmaceutical Inc. Announces Third Quarter 2025 Conference Call Ultragenyx Pharmaceutical Inc. will host a conference call on November 4, 2025, to discuss its Q3 financial results and corporate updates. Stakeholders are encouraged to participate to gain insights into the company's ongoing projects and future outlook.
October 24, 2025 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant for New Executives Ultragenyx Pharmaceutical has awarded 20,317 restricted stock units to 17 new executives to strengthen its leadership team. This strategic inducement grant aligns with the company's mission to develop therapies for rare diseases, promoting long-term commitment and innovation in drug development.
October 03, 2025 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant for New Executive Hire Ultragenyx Pharmaceutical Inc. has announced a significant inducement grant for a new executive hire, aiming to strengthen its leadership and commitment to developing treatments for rare diseases. The grant includes stock options and RSUs with a four-year vesting schedule, reinforcing the company's strategy in the biopharmaceutical sector.
September 30, 2025 Ultragenyx Pharmaceutical Inc. Welcomes Eric Olson as New Chief Business Officer Ultragenyx Pharmaceutical Inc. has appointed Eric Olson as Chief Business Officer, marking a strategic leadership transition. With extensive experience in biopharma, Olson aims to advance the company's mission to develop therapies for rare diseases.
August 06, 2025 Ultragenyx Pharmaceutical Inc. Reports Q2 2025 Financial Results: Growth Amidst Challenges Ultragenyx Pharmaceutical's Q2 2025 report shows total revenues of $166.5 million, driven by Evkeeza's success. Despite revenue growth, the company faces net losses and rising operating expenses while advancing its drug pipeline.
May 07, 2025 Ultragenyx Pharmaceutical Inc. Reports Q1 2025 Financial Results: A Focus on Growth Amidst Challenges Ultragenyx Pharmaceutical Inc. reported significant revenue growth in Q1 2025, driven by increased demand for its products despite ongoing net losses. The company is focused on advancing its clinical pipeline while managing operational costs effectively.
March 19, 2025 Ultragenyx Pharmaceutical Inc. Inducement Grant: A Strategic Move to Enhance Talent Acquisition Ultragenyx Pharmaceutical Inc. awarded 21,806 RSUs to 16 new hires as part of a strategic move to enhance talent acquisition. This initiative aims to align new employees' interests with company goals and foster long-term commitment in addressing rare diseases.
February 24, 2025 Ultragenyx Pharmaceutical Inc. Set to Engage Investors at March Conferences Ultragenyx Pharmaceutical Inc. is set to participate in three major investor conferences in March 2025, showcasing its commitment to rare disease therapies. Dr. Eric Crombez will lead discussions on the company’s strategic initiatives and product pipeline.
February 19, 2025 Ultragenyx Pharmaceutical Inc. Reports Strong Growth and Continued Investment in 2024 Annual Report Ultragenyx Pharmaceutical Inc. reported $560.2 million in revenues for 2024, showcasing strong growth driven by product demand. Despite substantial net losses, the company remains committed to innovation and strategic investments in research and development.
February 19, 2025 Ultragenyx Pharmaceutical Inc. Announces Inducement Grant for New Executives Ultragenyx Pharmaceutical Inc. has granted 23,760 restricted stock units to 10 newly hired non-executive officers as an inducement to attract top talent. This initiative aligns with the company's goals to strengthen its leadership and advance treatments for rare diseases.
February 18, 2025 Ultragenyx Pharmaceutical Inc. Sees Progress with FDA Acceptance of UX111 for Sanfilippo Syndrome Type A Ultragenyx Pharmaceutical has received FDA acceptance for Priority Review of its UX111 therapy, aimed at treating Sanfilippo syndrome type A. Promising clinical data demonstrates significant cognitive improvements and a favorable safety profile, marking a potential breakthrough for this devastating condition.
February 13, 2025 Ultragenyx Pharmaceutical Inc. Reports Robust Financial Results for Q4 and Full Year 2024 Ultragenyx Pharmaceutical Inc. reported robust financial results for Q4 and full year 2024, with a 29% revenue growth to $165 million in Q4. Despite increased operational expenses and a net loss, the company is optimistic about 2025, projecting further revenue growth and significant upcoming clinical milestones.
February 06, 2025 Ultragenyx Pharmaceutical Inc. Announces Upcoming Conference Call for Financial Results Ultragenyx Pharmaceutical Inc. will host a conference call on February 13, 2025, to discuss its Q4 2024 financial results and corporate developments. The call highlights the company's focus on innovative therapies for rare genetic diseases.
February 05, 2025 Ultragenyx Pharmaceutical Inc. Announces Promising Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A Ultragenyx Pharmaceutical's UX111 gene therapy demonstrates significant clinical improvements for children with Sanfilippo Syndrome Type A, with notable cognitive gains and reduced biomarkers. The treatment shows a favorable safety profile and is under FDA review for accelerated approval.
January 20, 2025 SWOT Analysis of Ultragenyx Pharmaceutical Inc. in 2025 This SWOT analysis of Ultragenyx Pharmaceutical Inc. in 2025 examines its strengths in addressing rare diseases, alongside weaknesses like operating losses. It also explores growth opportunities and threats from competition and regulatory challenges, underscoring the company's strategic position in the biopharmaceutical industry.
November 06, 2024 Ultragenyx Pharmaceutical Inc. Reports Q3 2024 Financial Results: A Step Forward in Rare Disease Treatment Ultragenyx Pharmaceutical Inc. reported strong Q3 2024 revenue growth of $139.5 million, driven by its existing therapies. Despite net losses, the company remains focused on expanding its clinical pipeline for rare diseases, with significant updates on key product candidates.
August 02, 2024 Ultragenyx Pharmaceutical Inc. Reports Q2 2024 Results: Continued Investment in Rare Diseases Amidst Financial Losses Ultragenyx Pharmaceutical's Q2 2024 results reveal a reduced net loss of $131.6 million and increased revenues of $147 million. The company continues to advance its promising pipeline for rare diseases while facing ongoing financial challenges.
May 03, 2024 Ultragenyx Pharmaceutical Inc. Reports Q1 2024 Financial Results: A Mixed Bag of Growth and Losses Ultragenyx Pharmaceutical Inc. reported a revenue increase to $108.8 million in Q1 2024, despite a net loss of $170.7 million. The company continues to invest heavily in its product pipeline for rare genetic diseases while facing ongoing financial challenges.
